614 related articles for article (PubMed ID: 27546731)
21. Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study.
Jeong YH; Kim IS; Park Y; Kang MK; Koh JS; Hwang SJ; Kwak CH; Hwang JY
JACC Cardiovasc Interv; 2010 Jul; 3(7):731-41. PubMed ID: 20650435
[TBL] [Abstract][Full Text] [Related]
22. CYP2C19 and CES1 polymorphisms and efficacy of clopidogrel and aspirin dual antiplatelet therapy in patients with symptomatic intracranial atherosclerotic disease.
Hoh BL; Gong Y; McDonough CW; Waters MF; Royster AJ; Sheehan TO; Burkley B; Langaee TY; Mocco J; Zuckerman SL; Mummareddy N; Stephens ML; Ingram C; Shaffer CM; Denny JC; Brilliant MH; Kitchner TE; Linneman JG; Roden DM; Johnson JA
J Neurosurg; 2016 Jun; 124(6):1746-51. PubMed ID: 26587656
[TBL] [Abstract][Full Text] [Related]
23. Impact of CYP2C19 Polymorphisms on Clinical Outcomes and Antiplatelet Potency of Clopidogrel in Caucasian Poststroke Survivors.
Tomek A; Matʼoška V; Frýdmanová A; Magerová H; Šrámek M; Paulasova-Schwabová J; Růžičková T; Janský P; Šarbochová I; Hadačová I; Kaplan V; Lacinová Z; Táborský L; Serebruany V
Am J Ther; 2018; 25(2):e202-e212. PubMed ID: 29509167
[TBL] [Abstract][Full Text] [Related]
24. Secondary Stroke Prophylaxis with Clopidogrel Produces Sufficient Antiplatelet Response.
Rath CL; Jørgensen NR; Wienecke T
J Stroke Cerebrovasc Dis; 2018 Oct; 27(10):2683-2690. PubMed ID: 29945766
[TBL] [Abstract][Full Text] [Related]
25. Associations of CYP3A4, NR1I2, CYP2C19 and P2RY12 polymorphisms with clopidogrel resistance in Chinese patients with ischemic stroke.
Liu R; Zhou ZY; Chen YB; Li JL; Yu WB; Chen XM; Zhao M; Zhao YQ; Cai YF; Jin J; Huang M
Acta Pharmacol Sin; 2016 Jul; 37(7):882-8. PubMed ID: 27133299
[TBL] [Abstract][Full Text] [Related]
26. Aspirin Versus Clopidogrel for Type 2 Diabetic Patients with First-Ever Noncardioembolic Acute Ischemic Stroke: Ten-Year Survival Data from the Athens Stroke Outcome Project.
Milionis H; Ntaios G; Papavasileiou V; Spengos K; Manios E; Elisaf M; Vemmos K
J Stroke Cerebrovasc Dis; 2017 Dec; 26(12):2769-2777. PubMed ID: 28756905
[TBL] [Abstract][Full Text] [Related]
27. Protocol for the comparison of triflusal and clopidogrel in secondary prevention of stroke based on cytochrome P450 2C19 genotyping (MASETRO study): A multicenter, randomized, open-label, parallel-group trial.
Han SW; Kim YJ; Ahn SH; Seo WK; Yu S; Oh SH; Kim YN; Lee KY;
Int J Stroke; 2016 Jun; 11(4):485-91. PubMed ID: 26763917
[TBL] [Abstract][Full Text] [Related]
28. Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes.
Furuta T; Iwaki T; Umemura K
Br J Clin Pharmacol; 2010 Sep; 70(3):383-92. PubMed ID: 20716239
[TBL] [Abstract][Full Text] [Related]
29. Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study.
Charlot M; Ahlehoff O; Norgaard ML; Jørgensen CH; Sørensen R; Abildstrøm SZ; Hansen PR; Madsen JK; Køber L; Torp-Pedersen C; Gislason G
Ann Intern Med; 2010 Sep; 153(6):378-86. PubMed ID: 20855802
[TBL] [Abstract][Full Text] [Related]
30. Association between platelet function and recurrent ischemic vascular events after TIA and minor stroke
.
Zhang J; Zhang J; Sun H; Ming T; Liu X; Cong Y; Li F; Li Z
Int J Clin Pharmacol Ther; 2017 Oct; 55(10):789-797. PubMed ID: 28766499
[TBL] [Abstract][Full Text] [Related]
31. Aspirin plus clopidogrel may reduce the risk of early neurologic deterioration in ischemic stroke patients carrying CYP2C19*2 reduced-function alleles.
Yi X; Zhou Q; Wang C; Lin J; Chai Z
J Neurol; 2018 Oct; 265(10):2396-2403. PubMed ID: 30128710
[TBL] [Abstract][Full Text] [Related]
32. Risk of major adverse cardiovascular events for concomitant use of clopidogrel and proton pump inhibitors in patients inheriting CYP2C19 loss-of-function alleles: meta-analysis.
Biswas M; Rahaman S; Biswas TK; Ibrahim B
Int J Clin Pharm; 2021 Oct; 43(5):1360-1369. PubMed ID: 33774763
[TBL] [Abstract][Full Text] [Related]
33. Risk of adverse cardiovascular outcomes and all-cause mortality associated with concomitant use of clopidogrel and proton pump inhibitors in elderly patients.
Mahabaleshwarkar RK; Yang Y; Datar MV; Bentley JP; Strum MW; Banahan BF; Null KD
Curr Med Res Opin; 2013 Apr; 29(4):315-23. PubMed ID: 23362935
[TBL] [Abstract][Full Text] [Related]
34. Esomeprazole with clopidogrel reduces peptic ulcer recurrence, compared with clopidogrel alone, in patients with atherosclerosis.
Hsu PI; Lai KH; Liu CP
Gastroenterology; 2011 Mar; 140(3):791-8. PubMed ID: 21144850
[TBL] [Abstract][Full Text] [Related]
35. Effect of individual proton pump inhibitors on cardiovascular events in patients treated with clopidogrel following coronary stenting: results from the Ibaraki Cardiac Assessment Study Registry.
Aihara H; Sato A; Takeyasu N; Nishina H; Hoshi T; Akiyama D; Kakefuda Y; Watabe H; Aonuma K;
Catheter Cardiovasc Interv; 2012 Oct; 80(4):556-63. PubMed ID: 22234956
[TBL] [Abstract][Full Text] [Related]
36. CYP2C19 polymorphisms and antiplatelet effects of clopidogrel in acute ischemic stroke in China.
Jia DM; Chen ZB; Zhang MJ; Yang WJ; Jin JL; Xia YQ; Zhang CL; Shao Y; Chen C; Xu Y
Stroke; 2013 Jun; 44(6):1717-9. PubMed ID: 23640828
[TBL] [Abstract][Full Text] [Related]
37. Cardiovascular outcomes associated with concomitant use of clopidogrel and proton pump inhibitors in patients with acute coronary syndrome in Taiwan.
Lin CF; Shen LJ; Wu FL; Bai CH; Gau CS
Br J Clin Pharmacol; 2012 Nov; 74(5):824-34. PubMed ID: 22364155
[TBL] [Abstract][Full Text] [Related]
38. Clopidogrel High On-Treatment Platelet Reactivity in Patients with Carotid Artery Stenosis Undergoing Endarterectomy. A Pilot Study.
Backovic D; Ignjatovic S; Rakicevic L; Novkovic M; Kusic-Tisma J; Radojkovic D; Strugarevic E; Calija B; Radak D; Kovac M
Curr Vasc Pharmacol; 2016; 14(6):563-569. PubMed ID: 27411384
[TBL] [Abstract][Full Text] [Related]
39. VASP phosphorylation and genetic polymorphism for clopidogrel resistance in Chinese patients with non-cardioembolic ischemic stroke.
Zhang S; Lai X; Li W; Xiong Z; Xu A; Xu A; Huang L
Thromb Res; 2014 Dec; 134(6):1272-7. PubMed ID: 25457586
[TBL] [Abstract][Full Text] [Related]
40. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.
Wallentin L; James S; Storey RF; Armstrong M; Barratt BJ; Horrow J; Husted S; Katus H; Steg PG; Shah SH; Becker RC;
Lancet; 2010 Oct; 376(9749):1320-8. PubMed ID: 20801498
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
